Abstract:Liver fibrosis is a key process in the progression of chronic liver disease to cirrhosis. Currently, early diagnosis and precise staging of liver fibrosis remain great challenges. Extracellular matrix (ECM) molecules expressed specifically during liver fibrosis are ideal targets for bioimaging and detection of liver fibrosis. Here, we report that fluorescent probes based on a nucleic acid aptamer (ZY-1) targeting cellular fibronectin (cFN), a critical ECM molecule significantly accumulating during liver fibrosis, are promising bioimaging agents for the staging of liver fibrosis. In the work, the outstanding binding affinity of ZY-1 to cFN was validated through an in vitro model of human-derived hepatic stellate cells (HSCs). Subsequently, we constructed different ZY-1-based fluorescent probes and explored the real-time imaging performance of these fluorescent probes in CCl 4 -induced mouse models of different liver fibrosis stages. The ZY-1-based fluorescent probes, for the first time, effectively identified and distinguished early-stage liver fibrosis (stage 3 of Ishak 6) from advanced liver fibrosis (stage 5 of Ishak 6). The proof-of-concept study provides compelling evidences that ZY-1-based probes are a promising tool for the early diagnosis and staging of liver fibrosis and paves the way for further development of clinical-related diagnosis strategies for fibrotic diseases of the liver and other organs. Statement of significance Currently, early diagnosis and accurate staging of liver fibrosis continue to present significant challenges. This study demonstrates that fluorescent probes based on the nucleic acid aptamer ZY-1, which targets cellular fibronectin (cFN)—a crucial extracellular matrix (ECM) molecule that significantly accumulates during liver fibrosis—are promising bioimaging agents for staging liver fibrosis. The ZY-1-based fluorescent probes effectively identified and differentiated early-stage liver fibrosis from advanced liver fibrosis. This proof-of-concept study not only provides compelling evidence that ZY-1-based probes show promise for the early diagnosis and staging of liver fibrosis but also paves the way for further investigations into the use of ZY-1 in detecting other diseases associated with cFN.

An activatable near-infrared molecular reporter for fluoro-photoacoustic imaging of liver fibrosis

Novel Strategy for Validating the Existence and Mechanism of the "gut-liver axis" in Vivo by a Hypoxia-Sensitive NIR Fluorescent Probe.

High-fidelity Imaging of Fatty Liver in Vivo with a Fluorescent and Photoacoustic Dual-Mode Probe by Taking Advantage of the Liver “first Pass Effect”

Liver-Targeted Near-Infrared Fluorescence/Photoacoustic Dual-Modal Probe for Real-Time Imaging of In Situ Hepatic Inflammation

Organ-Targeted Ionizable Lipid Nanoparticles Facilitate Sequence-Activated Fluorogenic Probe for Precise Imaging of Inflammatory Liver Disease

Γ-Glutamyltransferase-activatable Fluoro-Photoacoustic Reporter for Highly Sensitive Diagnosis of Acute Liver Injury and Tumor.

A FAPα-activated MRI nanoprobe for precise grading diagnosis of clinical liver fibrosis

An activatable probe for detecting alcoholic liver injury <i>via</i> multispectral optoacoustic tomography and fluorescence imaging

Activatable Optical Probes for Fluorescence and Photoacoustic Imaging of Drug‐Induced Liver Injury

A<sub>2</sub>O<sub>2</sub>-activatable nanoprobe for diagnosing interstitial cystitis and liver ischemia-reperfusion injury via multispectral optoacoustic tomography and NIR-II fluorescent imaging

Ultrasound molecular imaging with cRGD-PLGA-PFOB nanoparticles for liver fibrosis staging in a rat model.

Molecular Fluorescent Probes for Liver Tumor Imaging

Cellular fibronectin-targeted fluorescent aptamer probes for early detection and staging of liver fibrosis

Non-invasive diagnosis of liver fibrosis via MRI using targeted gadolinium-based nanoparticles

Constructing a novel fluorescence detection method for γ-glutamyltranspeptidase and application on visualizing liver injury

De Novo Design of Activatable Photoacoustic/Fluorescent Probes for Imaging Acute Lung Injury in Vivo.

A H 2 O 2 -activatable nanoprobe for diagnosing interstitial cystitis and liver ischemia-reperfusion injury via multispectral optoacoustic tomography and NIR-II fluorescent imaging

An Activatable Semiconducting Nanoprobe for Early and Accurate Diagnosis of Liver Injury

A hyaluronic acid-derived imaging probe for enhanced imaging and accurate staging of liver fibrosis

Activatable Probes for Diagnosing and Positioning Liver Injury and Metastatic Tumors by Multispectral Optoacoustic Tomography

Engineering a Ratiometric Photoacoustic Probe with a Hepatocyte-Specific Targeting Ability for Liver Injury Imaging.